Skip to content
drillr.ai

REPL

Replimune Group, Inc.

NASDAQ · USHealthcareBiotechnology
$10.51+2.74%

Price as of Jul 20, 2026

REPL news

Replimune Group, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

    SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Replimune Group, Inc. (NASDAQ: REPL) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held Replimune shares continuously since prior to November 22, 2024, may have standing to seek corporate governance reforms, the return of funds back to the company, and a court-approved incentive award, al

    Globe Newswire ·

  2. Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

    WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting. Key findings are detailed below. Oral Presentation: RP2 oncolytic immunotherapy alone and in

    Globe Newswire ·

  3. Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

    WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting. “The overall survival analysis from IGNYTE shows that nearly half of all

    Globe Newswire ·

  4. Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

    WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path forward for resubmission and reconsideration of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab f

    Globe Newswire ·

  5. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ:REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Replimune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here

    ACCESSWIRE ·

  6. REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm

    LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm (https://www.globenewswire.com/Tracker?data=yOQeirEWDveDWcWgEGaXtwtg8ZiYobymy9RNM9cHuuumXcn864lcDRmCa7tdp9usitDp0FnUryavKy3LUrNfb-DvFqQ9PYYdVYC9kF1Pyyw=), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL (https://www.globenewswire.com/Tracker?data=pMDi7KGvJPLAnkijGwc7X2WsWBdylCXP2QHt0e4-8FU0s03L2sa5e

    Globe Newswire ·

  7. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

    NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Replimune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class ac

    Globe Newswire ·

  8. Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 29, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  9. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 27, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  10. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Investors to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 24, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  11. Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 23, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  12. Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Investors to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 22, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  13. Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  14. Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Investors to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 20, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  15. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Investors to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 19, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  16. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Stockholders to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 17, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  17. Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Stockholders to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April 16, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL. (https://bgandg.com/REPL/?utm_source=accesswire&utm_medium=pressrelease&utm_cam

    ACCESSWIRE ·

  18. Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

    SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Replimune Group, Inc. (NASDAQ: REPL). The investigation focuses on Replimune’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Replimune securities? If you purchased Replimune securities and suffered losses on your investment, join our investigation now: Click here to join the investigation (https://www.

    Globe Newswire ·

  19. Replimune to Present at Two Upcoming Investor Conferences

    WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Fireside Chat Time: 2:20 pm EDT Jefferies 2026 Biotech on the Beach Summit Date: Tuesday, Mar

    Globe Newswire ·